Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.92+0.22 (+3.86%)
Close on Nov 18, 2026Market cap $769.50MP/E –Yield –
Cytek Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cytek Biosciences's revenue for the twelve months ending Jun 30, 2026 was $206.71M, up 5.4% year over year. For fiscal 2025 it was $201.49M, up 0.5% from the year before. The highest annual figure on record is $201.49M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.49M | +0.5% |
| FY2024 | Dec 31, 2024 | $200.45M | +3.9% |
| FY2023 | Dec 31, 2023 | $193.02M | +17.7% |
| FY2022 | Dec 31, 2022 | $164.04M | +7421.1% |
| FY2021 | Dec 31, 2021 | $2.18M | +207.2% |
| FY2020 | Dec 31, 2020 | $710.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $48.14M | +5.6% |
| Q1 FY2026 | Mar 31, 2026 | $44.14M | +6.5% |
| Q4 FY2025 | Dec 31, 2025 | $62.14M | +8.1% |
| Q3 FY2025 | Sep 30, 2025 | $52.29M | +1.5% |
| Q2 FY2025 | Jun 30, 2025 | $45.60M | -2.2% |
| Q1 FY2025 | Mar 31, 2025 | $41.46M | -7.6% |
| Q4 FY2024 | Dec 31, 2024 | $57.48M | -1.3% |
| Q3 FY2024 | Sep 30, 2024 | $51.50M | +7.3% |
| Q2 FY2024 | Jun 30, 2024 | $46.62M | -6.2% |
| Q1 FY2024 | Mar 31, 2024 | $44.86M | +21.0% |
| Q4 FY2023 | Dec 31, 2023 | $58.23M | +20.5% |
| Q3 FY2023 | Sep 30, 2023 | $48.00M | +18.6% |
| Q2 FY2023 | Jun 30, 2023 | $49.69M | +23.7% |
| Q1 FY2023 | Mar 31, 2023 | $37.09M | +5.8% |
| Q4 FY2022 | Dec 31, 2022 | $48.34M | +24.3% |
| Q3 FY2022 | Sep 30, 2022 | $40.48M | +17.7% |
| Q2 FY2022 | Jun 30, 2022 | $40.16M | +32.1% |
| Q1 FY2022 | Mar 31, 2022 | $35.06M | +44.5% |
| Q4 FY2021 | Dec 31, 2021 | $38.89M | +27.0% |
| Q3 FY2021 | Sep 30, 2021 | $34.38M | +37.0% |
| Q2 FY2021 | Jun 30, 2021 | $30.41M | +58.9% |
| Q1 FY2021 | Mar 31, 2021 | $24.27M | – |
| Q4 FY2020 | Dec 31, 2020 | $30.62M | – |
| Q3 FY2020 | Sep 30, 2020 | $25.10M | – |
| Q2 FY2020 | Jun 30, 2020 | $19.14M | – |
See a number that looks wrong?